160 related articles for article (PubMed ID: 10681718)
1. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin.
Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
Haematologica; 2000 Feb; 85(2):124-32. PubMed ID: 10681718
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
[TBL] [Abstract][Full Text] [Related]
3. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
Suárez L; Vidriales MB; Moreno MJ; López A; García-Laraña J; Pérez-López C; Tormo M; Lavilla E; López-Berges MC; de Santiago M; San Miguel JF; Orfao A;
Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
[TBL] [Abstract][Full Text] [Related]
4. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
5. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
7. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
8. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
[TBL] [Abstract][Full Text] [Related]
10. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.
Oyan AM; Bø TH; Jonassen I; Ulvestad E; Gjertsen BT; Kalland KH; Bruserud O
Cytometry B Clin Cytom; 2005 Mar; 64(1):18-27. PubMed ID: 15668952
[TBL] [Abstract][Full Text] [Related]
11. Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts.
Bruserud Ø; Huang TS; Glenjen N; Gjertsen BT; Foss B
Haematologica; 2002 Jun; 87(6):584-95. PubMed ID: 12031914
[TBL] [Abstract][Full Text] [Related]
12. Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
Vial JP; Tabrizi R; Pigneux A; Lacombe F; Praloran V; Belloc F
Cytometry B Clin Cytom; 2006 May; 70(3):115-23. PubMed ID: 16572429
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia.
Skorokhod OA; Garmaeva TTs; Vitvitsky VM; Isaev VG; Parovichnikova EN; Savchenko VG; Ataullakhanov FI
Med Sci Monit; 2004 Apr; 10(4):PI55-64. PubMed ID: 15039656
[TBL] [Abstract][Full Text] [Related]
14. [The immunophenotypic and cytogenetic characteristics of the blast cells in subvariants of acute myeloid leukemia].
Isakova LM; Tretiak NN; Khromiak VN; Gordienko AI; Zverkova AS; Vakul'chuk AM
Tsitol Genet; 2000; 34(1):48-56. PubMed ID: 10808542
[TBL] [Abstract][Full Text] [Related]
15. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
[TBL] [Abstract][Full Text] [Related]
19. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
